My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024-136
CBCC
>
Official Documents
>
2020's
>
2024
>
2024-136
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
11/26/2024 2:04:55 PM
Creation date
7/11/2024 11:58:20 AM
Metadata
Fields
Template:
Official Documents
Official Document Type
Addendum
Approved Date
06/18/2024
Control Number
2024-136
Agenda Item Number
12.C.1.
Entity Name
RxBenefits, Inc. (f/k/a Prescription Benefits, Inc.)
Subject
Addendum to Administrative Services Agreement for Group Insurance FY 24/25
Document Relationships
2024-137
(Cover Page)
Path:
\Official Documents\2020's\2024
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
26
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Docusign Envelope ID: 4C1 95600-904A-41 DA-A041-3005C422FD42 <br />DocuSign Envelope ID: 7CEFA800S9DE-49DA-8C5B-D8DB41083547 <br />(I/2024 Version) <br />17. At no charge, ESI must be able to transfer data to Client's other vendor partners (e.g., medical plan <br />administrator, stop loss vendor, disease management vendor, catastrophic claimant advocate, etc.), with an <br />appropriate non -disclosure agreement in place. <br />18. ESI can provide the fiilly identified NCPDP expanded format to Client's consultant on a monthly basis at no <br />additional charge for use by both the InfoLock team and the Pharmacy Analytics Team. <br />19. InfoLock Data and Pharmacy Analytics team feeds that are in place will be honored even after termination at <br />no cost to Client or Client's consultant. In other words, if the Agreement is not renewed following the Term, <br />InfoLock must still receive the 4th quarter data even though it will not be available until after termination of <br />this Agreement. <br />AUDITS <br />20. Third Party Audits- Client may employ a third -party auditor, at Client's sole cost and expense, to conduct <br />audits of the terms of this Exhibit A, including, but not limited to: <br />Pharmacy Claims transactions <br />Financial performance guarantees <br />21. Client's consultant (Lockton) may perform a pre -implementation audit prior to the Effective Date. <br />MISCELLANEOUS <br />22. Any costs bidding entities may incur as it relates to attending meetings, site visits or negotiations are the <br />responsibility of Administrator. <br />23. Client may not terminate this Agreement without cause and may only terminate this Agreement as expressly <br />provided for in Article Vl of the Agreement. <br />24. Coordination of Benefits claims accounted for in the claims data and discount guarantees by a flag indicating <br />that a transaction utilized COB functionality within the RxCLAIM system. COB claims are excluded from <br />pricing guarantees but are assessed an administrative fee if applicable. <br />G. EXECUTION BY CLIENT <br />Client hereby represents and warrants that the information contained in Section A of this Client Application <br />is true and correct in all respects and Client hereby agrees to the specific terms, conditions and financial arrangements <br />set out in this Exhibit A (Client Application). Client agrees that if any information in Section A changes, Client will <br />give Administrator prompt notice of such changes. Furthermore, Client understands that this Exhibit A (Client <br />Application) is a part of the Administrative Services Agreement between Client and Administrator to which it is <br />attached and incorporated into by reference and that Client is bound by all terms and conditions of such Administrative <br />Services Agreement. <br />All capitalized terms used in this Exhibit A (Client Application) but not specifically defined herein shall have <br />the meanings given to such terms in the Administrative Services Agreement to which this Exhibit A (Client <br />Application) is attached and made a part of. <br />23 <br />NOT FOR DISTRIBUTION. THE INFORMATION CONTAINED HEREIN IS CONFIDENTIAL, PROPRIETARY <br />AND CONSTITUTES TRADE SECRETS OF ESI AND RXBENEFITS <br />
The URL can be used to link to this page
Your browser does not support the video tag.